Alder BioPharmaceuticals Inc

Most Recent

• 

  .

  Company & Industry Overviews

  Competition Dynamics for Ajovy—Teva’s Migraine Drug

  Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

• 

  .

  Company & Industry Overviews

  What’s the Latest on Teva’s Fremanezumab?

  Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches.

• 

  .

  Company & Industry Overviews

  What Will Help Eli Lilly Build a Stronger Migraine Portfolio?

  In September, Eli Lilly presented the results of its phase-3 Spartan trial, in which Lasmiditan demonstrated significant progress in the treatment of migraines.

• 

  .

  Company & Industry Overviews

  Biotechnology ETFs: Who Were the Top Performers Last Week?

  Biotechnology ETFs rose during the week ending April 1, 2016. The SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology ETF (IBB) rose 6.2% and 5.0%, respectively.

• 

  .

  Company & Industry Overviews

  How are IBB’s Subgroups Performing?

  The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.